Engineered immune cells take on lupus in first human trial

NCT ID NCT06333483

First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This early-stage study tests a new treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't responded to other therapies. Obe-cel uses a patient's own immune cells, modified to target and attack faulty B cells driving the disease. The trial aims to check safety and see if it can bring lupus into remission, though ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Addenbrookes Hospital

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

    Contact Email: •••••@•••••

  • Great Ormond Street Hospital

    RECRUITING

    London, WC1N 3JH, United Kingdom

    Contact Email: •••••@•••••

  • Hospital Universitari Vall Hebrón

    RECRUITING

    Barcelona, 08035, Spain

    Contact Email: •••••@•••••

  • Hospital Universitari i Politecnic La Fe

    RECRUITING

    Valencia, 106046026, Spain

    Contact Email: •••••@•••••

  • Manchester Royal Infirmary, Manchester University NHS Foundation Trust,

    RECRUITING

    Manchester, M13 9WL, United Kingdom

    Contact Email: •••••@•••••

  • University College London Hospitals NHS Foundation Trust

    RECRUITING

    London, NW1 2PG, United Kingdom

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.